Undisclosed mutant selective ErbB2 inhibitor / Cogent Biosci - LARVOL DELTA

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) - "Upcoming Milestones...Present initial clinical data from SUMMIT, a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 clinical trial of bezuclastinib in patients with NonAdvSM in the second half of 2023. Clinical data is expected to include safety/tolerability, pharmacokinetics and measures of clinical activity. Present updated preclinical data from Cogent’s selective FGFR2 and ErbB2 research programs at the American Association for Cancer Research annual meeting taking place April 14-19, 2023 in Orlando, Florida."

P2 data • Preclinical • Aggressive Systemic Mastocytosis • Oncology • Solid Tumor

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting (GlobeNewswire) - "The first poster discussion will provide an update on Cogent’s next-generation fibroblast growth factor receptor 2 (FGFR2) program, which retains potency across all primary, gatekeeper and molecular brake resistance mutations. The poster includes an overview of ongoing optimization of the Cogent lead series, pharmacokinetic and pharmacodynamic assessment of an FGFR1-sparing novel molecule, as well as robust efficacy in model of FGFR2 clinical resistance (N549K)....The second poster will provide initial preclinical results from Cogent’s novel ErbB2 mutant selective program....Cogent’s exemplar molecule demonstrates robust cellular inhibition of all key resistance and primary driver mutations, while sparing wild type EGFR target engagement. In addition, the advanced compound demonstrates dose ascendable pharmacokinetics, robust tumor phospho-ErbB2 suppression (L755S), and superior tumor growth inhibition when compared to tucatinib."

PK/PD data • Preclinical • Oncology • Solid Tumor